drugs will be increasingly used in clinical practice and, therefore, patients will wish to become pregnant while receiving those treatments.

In consequence, it is an urgent need to get information about the safety of those new treatments during pregnancy and in children development. In addition, special situations such as multiple gestations should also be considered, as their outcome in IBD is largely unknown. To that aim, prospective multicenter registries are warranted and eagerly awaited.

CONFLICT OF INTEREST

Guarantor of the article: M Chaparro and Javier P. Gisbert.

Specific author contributions: M Chaparro and Javier P. Gisbert wrote the letter and approved the final version.

Financial support: None.

Potential competing interests: MCh has served as a speaker, or has received research or education funding from MSD, Abbvie, Hospira, Pfizer, Takeda, Janssen, Ferring, Shire Pharmaceuticals, Dr. Falk Pharma, and Tillotts Pharma. JPG has served as a speaker, a consultant and advisory member for or has received research funding from MSD, Abbvie, Hospira, Pfizer, Kern Pharma, Biogen, Takeda, Janssen, Roche, Ferring, Faes Farma, Shire Pharmaceuticals, Dr. Falk Pharma, Tillotts Pharma, Chiesi, Casen Fleet, Gebro Pharma, Otsuka Pharmaceutical, and Vifor Pharma.

REFERENCES

1. Kane, S and Becker, B. Anti-TNF exposure in utero, what about my twins? *Am J Gastroenterol.* 2018. <https://www.nature.com/articles/s41395-018-0165-x>
2. Chaparro M, Verreth A, Lobaton T, et al. Long-term safety of in utero exposure to anti-TNFalpha drugs for the treatment of inflammatory bowel disease: results from the Multicenter European TEDDY Study. *Am J Gastroenterol.* 2018;113:396–403.

Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), Gastroenterology Unit, Hospital Universitario de La Princesa, Instituto de Investigación Sanitaria Princesa (IIS-IP), Universidad Autónoma de Madrid, Madrid, Spain.
Correspondence: M.C. (email: mariachs2005@gmail.com)

The Best Surveillance Intervals for Detection of Intestinal Metaplasia and Dysplasia after Successful Endoscopic Eradication Therapy of Barrett's Esophagus

Bo Zhang, BM¹, Qiong Wu, BM¹,
You Lang Zhou, MD, PhD² and Ran Xu, BM¹

Am J Gastroenterol <https://doi.org/10.1038/s41395-018-0276-4>

To the Editor We read the article “Higher rate of Barrett's detection in the first year after successful endoscopic therapy: meta-analysis” with great interest [1]. Sawas et al. [1] found that detection rate of intestinal metaplasia (IM) and dysplasia after successful endoscopic eradication therapy (EET) of Barrett's esophagus (BE) was significantly higher within the first year of surveillance compared to the surveillance years that followed. EET as the first-line treatment for BE with dysplasia is highly effective if dysplasia or early cancer is found [2]. However, as the authors mentioned that current surveillance intervals after complete remission of IM (CRIM) were based on expert opinion, which made the detection rate of IM, and dysplasia after successful EET of BE quite unstable. Therefore, the author's findings have great reference value for judging the surveillance

intervals after achieving CRIM with endoscopic therapy. We conducted a cumulative meta-analysis according to the data provided by the authors to further support the authors' conclusions.

The cumulative meta-analysis is used to determine the point where further similar studies are unlikely to change the confirmed conclusions [3]. In our cumulative meta-analysis, studies were added one at a time according to the order of published year, and the aggregate effect estimate was recalculated after addition of each study. Our cumulative meta-analysis showed that IM detection rate in the first year was not significantly higher compared to all the subsequent years after until adding a 2017 study by Cotton et al. [4] (RR = 1.52, 95% confidence interval (CI): 1.11–2.08, Fig. 1a), and thereafter, the results remained stable. Figure 1b showed a forest plot for the cumulative meta-analysis of dysplasia detection rate after achieving CRIM between the first year and the subsequent years. A statistically significant difference was first achieved by adding a 2014 study by Conio et al. [5] (RR = 2.44, 95% CI: 1.02–5.83). Thereafter, seven more studies published between the years 2014 and 2017 made the difference not statistically significant (RR = 1.52, 95% CI: 0.96–2.41), while an essential change occurred when the study by Cotton et al. [4] published in 2017 was added (RR = 1.84, 95% CI: 1.22–2.79), and thereafter, this result that dysplasia detection rate was significantly higher in the first year compared to the subsequent years has remained stable after adding three studies published in 2017 and 2018 (RR = 1.90, 95% CI: 1.31–2.76). Regardless of which study was added, the difference in high-grade dysplasia (HGD)/esophageal adenocarcinoma (EAC) detection rate between the first year and all the subsequent years remained not statistically significant (data not shown).

The results of cumulative meta-analysis can help researchers justify additional studies or realize the need to reorient their research [6]. Our cumulative meta-analysis confirmed again that IM and dysplasia detection rate after achieving CRIM in the first year was significantly higher compared to all the subsequent years after. Relevant studies might not be needed for supporting

Fig. 1 **a** Forest plot comparison between the incidence rate of IM detection in the first year and all the subsequent years after. **b** Forest plot comparison between the incidence rate of dysplasia detection in the first year and all the subsequent years after. IM intestinal metaplasia, CI confidence interval, RR relative risk

these results. However, the conclusion that the difference in HGD/EAC detection rate between the first year and all

the subsequent years not statistically significant still requires a lot of research to further confirm.

CONFLICT OF INTEREST

Guarantor of the article: You Lang Zhou, MD, PhD.

Specific author contributions: Study concept and design: Y.L.Z.; acquisition of data for meta-analysis: B.Z. and Q.W.; analysis and interpretation of data: B.Z., Q.W. and R.X.; drafting of the manuscript: B.Z. and Q.W.; critical revision of the manuscript for important intellectual content: Y.L.Z.; statistical analysis: B.Z. and Q.W.; study supervision: Y.L.Z.

Financial support: This work was supported by Jiangsu Youth Medical Talent Project (QNRC2016702) and Key Research and Development Projects of Jiangsu Province (BE2017681).

Potential competing interests: None.

REFERENCES

1. Sawas T, Iyer PG, Alsawas M, et al. Higher rate of Barrett's detection in the first year after successful endoscopic therapy: meta-analysis. *Am J Gastroenterol*. 2018;113:959–971.
2. Desai M, Saligram S, Gupta N, et al. Efficacy and safety outcomes of multimodal endoscopic eradication therapy in Barrett's esophagus-related neoplasia: a systematic review and pooled analysis. *Gastrointest Endosc*. 2017;85:482–95.e4.
3. Clarke M, Brice A, Chalmers I. Accumulating research: a systematic account of how cumulative meta-analyses would have provided knowledge, improved health, reduced harm and saved resources. *PLoS ONE*. 2014;9:e102670.
4. Cotton CC, Wolf WA, Overholt BF, et al. Late recurrence of Barrett's esophagus after complete eradication of intestinal metaplasia is rare: final report from ablation in intestinal metaplasia containing dysplasia trial. *Gastroenterology*. 2017;01:01.
5. Conio M, Fisher DA, Blanche S, et al. One-step circumferential endoscopic mucosal cap resection of Barrett's esophagus with early neoplasia. *Clin Res Hepatol Gastroenterol*. 2014;38:81–91.
6. Haapakoski R, Mathieu J, Ebmeier KP, et al. Cumulative meta-analysis of interleukins 6 and 1 β , tumour necrosis factor alpha and C-reactive protein in patients with major depressive disorder. *Brain Behav Immun*. 2015;49:206–15.

¹The Hand Surgery Research Center, Affiliated Hospital of Nantong University, Medical School of Nantong University, 226001, Nantong, China. ²The Hand Surgery Research Center, Department of Hand Surgery, Affiliated Hospital of Nantong University, 226001, Nantong, China. These authors contributed equally: Bo Zhang, Qiong Wu. **Correspondence:** Y.L.Z. (email: zhouyoulang@ntu.edu.cn)